BrainStorm Q1 net loss $2.9M; advances NurOwn Phase 3b trial with IND amendment

BRAINSTORM CELL THERAPEUTICS INC.

2025-Q1 EPS reported -$0.45 vs consensus -$0.99 ▲ beat (+54.5%)

Net loss of $2.9M ($0.45/share) improved vs $3.4M ($0.75/share) in Q1 2024.
Cash, equivalents restricted cash $1.8M at March 31, 2025; R&D $1.3M, G&A $1.8M.
Submitted IND amendment for Phase 3b NurOwn trial (ENDURANCE) targeting ~200 early ALS patients with SPA.
Trial listed on ClinicalTrials.gov (NCT06973629) with 15 clinical sites; data at ISCT and ALS Summit.
Conference call rescheduled to May 19, 2025 at 8:30 AM ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.